ONE-WAYDated event · through FY2020
Development of an Alzheimer’s disease therapeutic using antibodies specific to toxic Aβ oligomers
An individual Alzheimer's disease drug-discovery program focused on an Aβ toxic oligomer-specific antibody, covering efficacy and pharmacology studies, patent filings, ELISA kit sales, joint development and licensing out.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.
PeriodFY2018-Q1 →Last written FY2020
Directionhelps1 helps · 0 hurts · 0 flat